⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

October 1, 2024

Supplementary Figure S3 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol

Laurien J. Zeverijn Birgit S. Geurts Thomas Battaglia Jade M. van Berge Henegouwen Gijs F. de Wit Louisa R. Hoes Hanneke van der Wijngaart Vincent van der Noort Paul Roepman Wendy W.J. de Leng Anne M.L. Jansen Myriam Chalabi Carla M.L. van Herpen Lot A. Devriese Frans Erdkamp Mariëtte Labots Maja J.A. de Jonge Emile D. Kerver Adriaan D. Bins Lindsay V.M. Leek Jessica C.L. Notohardjo Alfons J.M. van den Eertwegh Lodewyk F.A. Wessels Henk M.W. Verheul Hans Gelderblom Joris van de Haar Emile E. Voest

View at Publisher

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Supplementary Figure S3. Association between immune marker gene expression and clinical benefit to ICB.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zeverijn et al. (2024) studied this question.

synapsesocial.com/papers/68e56226e2b3180350efeeea https://doi.org/10.1158/1078-0432.27142396

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S2 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol2024
2Supplementary Figure S1 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol2024
3Data from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol2024
4Predictors of Immune Checkpoint Blockade Response in dMMR Colorectal Cancer Using an Integrated Immune-Enhanced Multi-Omics PlatformOriginal Research · 2026
5Supplemental Figure 2 from Transcriptomic Signatures of MSI-high Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors2024
6Supplemental Figure 2 from Transcriptomic Signatures of MSI-high Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors2024
7Supplementary Figure S1 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer2024
8Supplementary Figure S1 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer2024